Assessment of the Key Drivers of Cost-Effectiveness in the Economic Modelling of Canagliflozin (CANA) Versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting
Keyword(s):
Keyword(s):
Keyword(s):
2006 ◽
Vol 24
(S1)
◽
pp. 21-34
◽
Keyword(s):
2018 ◽
Vol 21
(3)
◽
pp. 611-621
◽
Keyword(s):
Keyword(s):
2017 ◽
Vol 19
(6)
◽
pp. 842-849
◽
Keyword(s):
Keyword(s):
Keyword(s):
2016 ◽
Vol 19
(12)
◽
pp. 1127-1134
◽